ID22177A - Senyawa sikloalkil, laktam, laton dan senyawa yang berhubungan, komposisi-komposisi farmasi yang mengandung yang sama, dan metode untuk menghambat pelepasan amiloid peptida dan atau sintesanya dengan menggunakan senyawa-senyawa tersebut - Google Patents

Senyawa sikloalkil, laktam, laton dan senyawa yang berhubungan, komposisi-komposisi farmasi yang mengandung yang sama, dan metode untuk menghambat pelepasan amiloid peptida dan atau sintesanya dengan menggunakan senyawa-senyawa tersebut

Info

Publication number
ID22177A
ID22177A IDW990563A ID990563A ID22177A ID 22177 A ID22177 A ID 22177A ID W990563 A IDW990563 A ID W990563A ID 990563 A ID990563 A ID 990563A ID 22177 A ID22177 A ID 22177A
Authority
ID
Indonesia
Prior art keywords
compounds
same
amiloid
synthes
peptides
Prior art date
Application number
IDW990563A
Other languages
English (en)
Inventor
Jing Wu
Jay S Tung
Eugene D Thorsett
Michael A Pleiss
Jeffrey S Nissen
Jeffrey Neitz
Lee H Latimer
Varghese John
Stephen Preedman
Thomas C Britton
James E Audia
Jon K Reel
Thomas E Mabry
Bruce A Dressman
Cynthai L Cwi
James J Droste
Steven S Henry
Stacey L Mcdaniel
William Leonard Scott
Russel D Stucky
Werren J Porter
Original Assignee
Werren J Porter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werren J Porter filed Critical Werren J Porter
Publication of ID22177A publication Critical patent/ID22177A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW990563A 1996-12-23 1997-12-22 Senyawa sikloalkil, laktam, laton dan senyawa yang berhubungan, komposisi-komposisi farmasi yang mengandung yang sama, dan metode untuk menghambat pelepasan amiloid peptida dan atau sintesanya dengan menggunakan senyawa-senyawa tersebut ID22177A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78002596A 1996-12-23 1996-12-23

Publications (1)

Publication Number Publication Date
ID22177A true ID22177A (id) 1999-09-09

Family

ID=25118329

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990563A ID22177A (id) 1996-12-23 1997-12-22 Senyawa sikloalkil, laktam, laton dan senyawa yang berhubungan, komposisi-komposisi farmasi yang mengandung yang sama, dan metode untuk menghambat pelepasan amiloid peptida dan atau sintesanya dengan menggunakan senyawa-senyawa tersebut

Country Status (28)

Country Link
EP (1) EP0951466B1 (id)
JP (1) JP3812952B2 (id)
KR (1) KR20000069654A (id)
CN (2) CN1171878C (id)
AR (1) AR010854A1 (id)
AT (1) ATE421509T1 (id)
AU (1) AU749658C (id)
BR (1) BR9714517A (id)
CA (1) CA2272305A1 (id)
CO (1) CO4930282A1 (id)
DE (1) DE69739236D1 (id)
DK (1) DK0951466T3 (id)
EA (1) EA002100B1 (id)
ES (1) ES2319239T3 (id)
HR (1) HRP970705A2 (id)
HU (1) HUP0001232A3 (id)
ID (1) ID22177A (id)
IL (2) IL158355A0 (id)
NO (1) NO993098L (id)
NZ (1) NZ335583A (id)
PE (1) PE52799A1 (id)
PL (1) PL196641B1 (id)
PT (1) PT951466E (id)
SI (1) SI0951466T1 (id)
TR (1) TR199901343T2 (id)
TW (1) TW568914B (id)
WO (1) WO1998028268A2 (id)
ZA (1) ZA9711537B (id)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999032453A1 (en) * 1997-12-22 1999-07-01 Elan Pharmaceuticals, Inc. POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6486350B1 (en) 1998-09-30 2002-11-26 Elan Pharmaceuticals Inc. Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2000038618A2 (en) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1226139A2 (en) 1999-07-06 2002-07-31 Vertex Pharmaceuticals Incorporated Cyclized amide derivatives for treating or preventing neuronal damage
EP1210338A2 (en) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
IL147774A0 (en) 1999-09-13 2002-08-14 Du Pont Pharm Co Hydroxyalkanoyl aminolactams and related structures as inhibitors of as protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
WO2001027108A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1230220A1 (en) * 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003523345A (ja) * 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
JP2003528150A (ja) * 2000-03-28 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのラクタム
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
EP1268434A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
EP1268433A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta-protein production
CA2404273A1 (en) 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
GB0025173D0 (en) * 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
JP2005538031A (ja) * 2000-11-17 2005-12-15 イーライ・リリー・アンド・カンパニー ラクタム化合物
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
IL156776A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
ATE356130T1 (de) 2001-01-17 2007-03-15 Amura Therapeutics Ltd Inhibitoren von cruzipain und anderen cysteinproteasen
WO2002057249A1 (en) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2840899B1 (fr) * 2002-06-12 2005-02-25 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
CA2505361A1 (en) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
EP1572660B1 (en) 2002-12-20 2011-01-26 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
FR2850380B1 (fr) 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
EP1636196A1 (en) 2003-03-14 2006-03-22 AstraZeneca AB Novel lactams and uses thereof
US7417152B2 (en) 2003-05-02 2008-08-26 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases
ITMI20032278A1 (it) 2003-11-21 2005-05-22 Ethicon Endo Surgery Inc Dispositivo di diagnosi
CA2547651C (en) * 2003-12-01 2015-06-23 Cambridge University Technical Services Limited Anti-inflammatory agents
AU2005217596B2 (en) 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
JP4519621B2 (ja) * 2004-11-30 2010-08-04 アイバイツ株式会社 光酸発生剤および感光性樹脂組成物
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CN101284828B (zh) * 2007-04-12 2011-04-27 中国科学院上海药物研究所 环庚烷并吡啶类化合物、其制备方法、用途及包含此类化合物的药物组合物
CN101778826B (zh) * 2007-08-14 2012-10-31 伊莱利利公司 作为γ分泌酶抑制剂的氮杂*衍生物
JP5539221B2 (ja) 2007-12-21 2014-07-02 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2389366A1 (en) * 2009-01-23 2011-11-30 Msd K.K. Benzodiazepin-2-on derivatives
AU2010216632A1 (en) * 2009-02-17 2011-08-04 Msd K.K. 1,4-benzodiazepin-2-on derivatives
AR079170A1 (es) 2009-12-10 2011-12-28 Lilly Co Eli Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR087107A1 (es) * 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
US9403763B2 (en) 2011-12-14 2016-08-02 Dana-Farber Cancer Institute, Inc. CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
CN103435549A (zh) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US9975848B2 (en) 2014-08-13 2018-05-22 The Trustees Of The University Of Pennsylvania Inhibitors of HIV-1 entry and methods of use thereof
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3013038A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
KR102418765B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
WO2017200762A2 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
EP3706754A1 (en) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
CN113754616B (zh) * 2021-09-27 2023-07-18 北京工商大学 一种反式-3-苯硫基-γ-内酯的制备方法
CN115656356B (zh) * 2022-09-30 2025-03-21 南京正济医药研究有限公司 4-羟基-7-苯氧基异喹啉-3-甲酸甲酯及其有关物质的测定方法
CN116116396B (zh) * 2023-02-20 2023-11-14 哈尔滨工程大学 一种偕胺肟基凝胶/氧化石墨/海绵复合材料的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE42215B1 (en) * 1973-12-28 1980-07-02 Fujisawa Pharmaceutical Co Azetidinone derivatives and process for preparation thereof
FR2278335A1 (fr) * 1974-07-04 1976-02-13 Fujisawa Pharmaceutical Co Derives d'azetidinones et leurs procedes de preparation
NZ264143A (en) * 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5849691A (en) * 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II

Also Published As

Publication number Publication date
NO993098L (no) 1999-08-20
JP2000511932A (ja) 2000-09-12
PL334305A1 (en) 2000-02-14
PL196641B1 (pl) 2008-01-31
EA199900593A1 (ru) 2000-02-28
HUP0001232A2 (hu) 2000-10-28
SI0951466T1 (sl) 2009-10-31
IL129820A0 (en) 2000-02-29
IL158355A0 (en) 2004-05-12
AU749658C (en) 2004-04-29
DK0951466T3 (da) 2009-03-16
ES2319239T3 (es) 2009-05-05
TW568914B (en) 2004-01-01
WO1998028268A2 (en) 1998-07-02
EP0951466A2 (en) 1999-10-27
NO993098D0 (no) 1999-06-22
BR9714517A (pt) 2000-07-04
CA2272305A1 (en) 1998-07-02
EA002100B1 (ru) 2001-12-24
DE69739236D1 (de) 2009-03-12
AU749658B2 (en) 2002-06-27
EP0951466B1 (en) 2009-01-21
CN1171878C (zh) 2004-10-20
PT951466E (pt) 2009-04-09
CN1242007A (zh) 2000-01-19
CO4930282A1 (es) 2000-06-27
ZA9711537B (en) 1998-06-25
TR199901343T2 (xx) 1999-09-21
JP3812952B2 (ja) 2006-08-23
PE52799A1 (es) 1999-05-27
HRP970705A2 (en) 1998-10-31
AR010854A1 (es) 2000-07-12
HUP0001232A3 (en) 2001-02-28
AU5700798A (en) 1998-07-17
NZ335583A (en) 2001-03-30
CN1616432A (zh) 2005-05-18
WO1998028268A3 (en) 1998-10-08
ATE421509T1 (de) 2009-02-15
KR20000069654A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
ID24929A (id) Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya
ID22852A (id) Bahan-bahan biokontrol antifungi, proses untuk membuatnya dan memperlakukannya
ID21045A (id) Asam amino termodifikasi, obat-obatan yang mengandung senyawa ini dan proses pembuatannya
ID26399A (id) Turunan 1-(1-tersubstitusi-4-piperidinil) metil -4-piperidin, proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan intermedietnya
ID25528A (id) Karboksamidotiazol tersubstitusi, pembuatannya dan komposisi farmasi yang mengandungnya
ID25543A (id) Alpha-aril-n-alkinitron dan komposisi farmasi yang mengandungnya
ID18046A (id) Senyawa siklik campuran, pembuatan dan penngunaannya.
ID17307A (id) Komposisi oral dan proses pembuatannya.
ID30299A (id) Turunan oksazolidinon, proses pembuatannya dan komposisi farmasi yang mengandungnya
ID20547A (id) Hasil adisi magnesium diklorida-alkohol, proses untuk penyediaannya dan komponen katalis yang dihasilkannya
BR9404433A (pt) Composição de cápsula, e composição detergente
ID24506A (id) Turunan-turunan 1,2,4-triazolo [4,3-b] pirido [3,2-d]-piridazina dan komposisi-komposisi farmasi yang mengandung senyawa tersebut
ID20604A (id) Polisakarida sintetis proses untuk pembuatan dan komposisi farmasi yang dikandungnya
ID29236A (id) Benzopiran-benzopiran dan benzoksepin-benzoksepin, komposisi-komposisi famaseutikal yang mengandungnya, dan proses penyiapannya
ID24520A (id) Analog-analog peptida lh-rh, penggunaannya dan komposisi farmasi yamg mengandungnya
DE59807505D1 (de) SUPRALEITERAUFBAU MIT HOCH-T c?-SUPRALEITERMATERIAL, VERFAHREN ZUR HERSTELLUNG DES AUFBAUS SOWIE STROMBEGRENZEREINRICHTUNG MIT EINEM SOLCHEN AUFBAU
ID16128A (id) Turunan arilglisinamida baru, proses pembuatannya dan komposisi-komposisi farmasi yang mengandung senyawa ini
TR199802394A3 (tr) Proteinleri stabilize etmek için gelistirilmis proses.
ID22911A (id) Turunan-turunan triazol baru, proses pembuatan dan komposisi-komposisi farmasi yang mengandungnya
ID16644A (id) Proses untuk membuat bagian atas wadah dengan penutup yang dapat dilepas dan dipakai sebagai kap.
ID17076A (id) Turunan 2,4-disubstitusi pirimidin, proses untuk pembuatan zat yang sama dan komposisi farmasi yang mengandung zat yang sama
DK0842991T3 (da) Grundersammensætning
ID23990A (id) Komposisi-komposisi pencuci asam yang mengandung amina-amina teralkoksilat dan penggunannya
BR9709406B1 (pt) fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas.
ID17875A (id) Komposisi farmasi yang mengandung asam 4-oksobutanoat